Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Monocytes, but not T cells, respond to insulin with Akt(S473) phosphorylation independent of the donor glucometabolic state.

Thewissen MM, van de Gaar J, den Boer AT, Munsters MJ, Blaak EE, Duijvestijn A.

Diabetes Metab Res Rev. 2014 May;30(4):323-32. doi: 10.1002/dmrr.2498.

PMID:
24302564
2.

Prevention of the metabolic syndrome in IGT subjects in a lifestyle intervention: results from the SLIM study.

den Boer AT, Herraets IJ, Stegen J, Roumen C, Corpeleijn E, Schaper NC, Feskens E, Blaak EE.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1147-53. doi: 10.1016/j.numecd.2012.12.005. Epub 2013 Feb 23.

3.

Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT.

Penn L, White M, Lindström J, den Boer AT, Blaak E, Eriksson JG, Feskens E, Ilanne-Parikka P, Keinänen-Kiukaanniemi SM, Walker M, Mathers JC, Uusitupa M, Tuomilehto J.

PLoS One. 2013;8(2):e57143. doi: 10.1371/journal.pone.0057143. Epub 2013 Feb 25.

4.

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.

Cancer Res. 2005 Aug 1;65(15):6984-9.

5.

Tuning immune responses: diversity and adaptation of the immunological synapse.

Friedl P, den Boer AT, Gunzer M.

Nat Rev Immunol. 2005 Jul;5(7):532-45. Review.

PMID:
15999094
6.

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ.

J Immunol. 2004 Dec 1;173(11):6753-9.

7.
8.

In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.

Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R.

J Immunol. 2002 Apr 15;168(8):3755-62.

9.

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. Epub 2002 Apr 2.

10.

Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.

Schurmans LR, Diehl L, den Boer AT, Sutmuller RP, Boonman ZF, Medema JP, van der Voort EI, Laman J, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2001 Nov 15;167(10):5832-7.

11.

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE.

J Immunol. 2001 Sep 1;167(5):2522-8.

12.

The role of CD40 in peripheral T cell tolerance and immunity.

Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE.

J Mol Med (Berl). 2000;78(7):363-71. Review.

PMID:
11043379
13.

Successful immunotherapy of an intraocular tumor in mice.

Schurmans LR, den Boer AT, Diehl L, van der Voort EI, Kast WM, Melief CJ, Toes RE, Jager MJ.

Cancer Res. 1999 Oct 15;59(20):5250-4.

14.

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.

Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE.

Nat Med. 1999 Jul;5(7):774-9.

PMID:
10395322
15.

Angelman syndrome without detectable chromosome 15q11-13 anomaly: clinical study of familial and isolated cases.

Laan LA, Halley DJ, den Boer AT, Hennekam RC, Renier WO, Brouwer OF.

Am J Med Genet. 1998 Mar 19;76(3):262-8. Review.

PMID:
9508247
16.

Angelman syndrome in adulthood.

Laan LA, den Boer AT, Hennekam RC, Renier WO, Brouwer OF.

Am J Med Genet. 1996 Dec 18;66(3):356-60.

PMID:
9072912

Supplemental Content

Loading ...
Support Center